Education and Training
- Hematology/Oncology Fellowship, Dartmouth Medical School, 2014 - 2017
- Pennsylvania Hospital, University of Pennsylvania School of Medicine, 2011 - 2014
- D.O., Philadelphia College of Osteopathic Medicine, 2011
Epperla, N, Maddocks, KJ, Salhab, M, Chavez, JC, Reddy, N, Karmali, R, Umyarova, E, Bachanova, V, Costa, C, Glenn, M, Calzada, O, Xavier, AC, Zhou, Z, Hossain, NM, Hernandez-Ilizaliturri, FJ, Al-Mansour, Z, Barta, SK, Chhabra, S, Lansigan, F, Mehta, A, Jaglal, MV, Evans, A, Flowers, CR, Cohen, JB, Fenske, TS, Hamadani, M, and Costa, LJ. "C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy." Cancer 123, no. 22 (November 15, 2017): 4411-4418.
Landsburg, DJ, Falkiewicz, MK, Maly, J, Blum, KA, Howlett, C, Feldman, T, Mato, AR, Hill, BT, Li, S, Medeiros, LJ, Torka, P, Hernandez-Ilizaliturri, F, Reddy, NM, Singavi, A, Fenske, TS, Chavez, JC, Kaplan, JB, Behdad, A, Petrich, AM, Bast, MA, Vose, JM, Olszewski, AJ, Costa, C, Lansigan, F, Gerson, JN, Barta, SK, Calzada, O, Cohen, JB, Lue, JK, Amengual, JE, Rivera, X, Persky, DO, Peace, DJ, Nathan, S, and Cassaday, RD. "Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission." Journal of Clinical Oncology 35, no. 20 (July 10, 2017): 2260-2267.
Costa, LJ, Maddocks, K, Epperla, N, Reddy, NM, Karmali, R, Umyarova, E, Bachanova, V, Costa, C, Glenn, MJ, Chavez, JC, Calzada, O, Lansigan, F, Nasheed, H, Barta, SK, Zhou, Z, Jaglal, M, Chhabra, S, Hernandez-Ilizaliturri, F, Xavier, AC, Mehta, A, Peker, D, Forero-Torres, A, Al-Mansour, Z, Evens, AM, Cohen, JB, Flowers, CR, Fenske, TS, and Hamadani, M. "Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies." American Journal of Hematology 92, no. 2 (February 2017): e24615-e24615.
Costa, CA, Zaki, BI, Yen, SP, Winer, ES, Ryan, H, Findley, D, Metzler, SR, Shaw, L, Tsui, A, MacKenzie, TA, Beaven, AW, and Lansigan, F. "Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival." December 2, 2016.